Top news of the day from across the health care landscape.
Pfizer’s new atopic dermatitis drug, abrocitinib, met its primary endpoints in a late-stage study evaluating the drug in patients 12 years of age and older with moderate-to-severe forms of the disease, Reuters reported. According to the article, abrocitinib achieved statistically significant improvement in clearing the skin of patients with atopic dermatitis compared with a placebo. The results of the study showed abrocitinib was consistently well tolerated, the article reported.
A new study showed glucosamine, a dietary supplement used for arthritic pain, may reduce the risk of heart disease, The New York Times reported. According to the article, the study examined 466,039 men and women who were free of cardiovascular disease at the start of the study and approximately 90,000 of them reported regular use of glucosamine. Compared with those who did not use the supplement, glucosamine users had an 18% lower risk of coronary heart disease and a 15% lower risk of any cardiovascular event, the article reported.
Most patients with migraine taking an oral, acute prescription medication reported unmet treatment needs in a large survey, The American Journal of Managed Care reported. Among 15,133 respondents with migraine, 26% reported use of oral acute prescription medications. Overall, the majority of respondents had at least 1 unmet need, reported unmet needs related to demanding attack characteristics, or had unmet needs related to inadequate treatment response, the article reported.